Publications

• Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion
  Filatenkov, A., Baker, J., Muller, A. M., Ahn, G.-O., Kohrt, H., & Strober, S. (2014). Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion. RADIATION RESEARCH, 182(2), 163-169.
• Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
  Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.
• Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.
  Müller, A. Ms., Poyser, J., Küpper, N. J., Burnett, C., Ko, R. M., & Shizuru, J. A. (2014). Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. Blood, 123(18), 2882-2892.
• B6.g7 mice reconstituted with BDC2 center dot 5 non-obese diabetic (BDC2 center dot 5NOD) stem cells do not develop autoimmune diabetes Rajasekaran, N., Wang, N., Hang, Y., Macaubas, C., Rinderknecht, C., & Mellins, E. D. (2013). B6.g7 mice reconstituted with BDC2 center dot 5 non-obese diabetic (BDC2 center dot 5NOD) stem cells do not develop autoimmune diabetes. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 174(1), 27-37.
  
• Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice Wang, Y., Chen, X., Tsai, S., Thomas, A., Shizuru, J. A., & Cao, T. M. (2013). Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice. IMMUNOGENETICS, 65(8), 585-596.
  
• Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice Chen, X., Wang, Y., Li, Q., Tsai, S., Thomas, A., & Cao, T. M. (2013). Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice. IMMUNOGENETICS, 65(8), 597-607.
  
• Host-derived CD4+T cells attenuate stem cellmediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice Rajasekaran, N., Wang, N., Phi Truong, P., Rinderknecht, C., Macaubas, C., & Mellins, E. D. (2013). Host-derived CD4+T cells attenuate stem cellmediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice. ARTHRITIS AND RHEUMATISM, 65(3), 681-692.
  
• The road to purified hematopoietic stem cell transplants is paved with antibodies. Logan, A. C., Weissman, I. L., & Shizuru, J. A. (2012). The road to purified hematopoietic stem cell transplants is paved with antibodies. Current opinion in immunology, 24(5), 640-648.
  
• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.
  
• Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., & Strober, S. (2012). Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants. AMERICAN JOURNAL OF TRANSPLANTATION, 12(5), 1133-1145.
  
• Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity Mueller, A. Ms., Shashidhar, S., Kuepper, N. J., Kohrt, H. Ek., Florek, M., & Shizuru, J. A. (2012). Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(15), 5820-5825.
  
• Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., & Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581-588.
  
• Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516-521.
  
• Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells Mueller, A. Ms., Kohrt, H. Ek., Cha, S., Laport, G., Klein, J., & Shizuru, J. A. (2012). Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), 125-133.
  
• Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.
  
• A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies Chen, G. L., Arai, S., Flowers, M. Ed., Otani, J. M., Qiu, J., & Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070-4078.
  
• Rapid Reconstitution of Antibody Responses Following Transplantation of Purified Allogeneic Hematopoietic Stem Cells Linderman, J. A., & Shizuru, J. A. (2011). Rapid Reconstitution of Antibody Responses Following Transplantation of Purified Allogeneic Hematopoietic Stem Cells. JOURNAL OF IMMUNOLOGY, 186(7), 4191-4199.
  
• Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., & Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192-199.
  
• Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Müller, A. Ms., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14721-14726.
  
• Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.
  
• Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas Shustov, A. R., Gooley, T. A., Sandmaier, B. M., Shizuru, J., Sorror, M. L., & Maloney, D. G. (2010). Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. BRITISH JOURNAL OF HAEMATOLOGY, 150(2), 170-178.
  
• Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia Gyurkocza, B., Storb, R., Storer, B. E., Chauncey, T. R., Lange, T., & Sandmaier, B. M. (2010). Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 28(17), 2859-2867.
  
• Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., & Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303-309.
  
• The biology of allogeneic hematopoietic cell resistance. Shizuru, J. A., Bhattacharya, D., & Cavazzana-Calvo, M. (2010). The biology of allogeneic hematopoietic cell resistance. Biology of blood and marrow transplantation , 16(1), S2-7.
  
• Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation Filatenkov, A., Mueller, A. Ms., Tseng, W. W.-L., Dejbakhsh-Jones, S., Winer, D., & Strober, S. (2009). Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation. JOURNAL OF IMMUNOLOGY, 183(11), 7196-7203.
  
• Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Gyurkocza, B., Cao, T. M., Storb, R. F., Lange, T., Leisenring, W., & Sandmaier, B. M. (2009). Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(10), 1314-1322.
  
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.
  
• A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice Cao, T. M., Thomas, A., Wang, Y., Tsai, S., Logronio, K., & Shizuru, J. A. (2009). A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice. BLOOD, 114(1), 202-210.
  
• Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice Cao, T. M., Lazzeroni, L. C., Tsai, S., Pang, W. W., Kao, A., & Shizuru, J. A. (2009). Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice. JOURNAL OF IMMUNOLOGY, 183(1), 462-469.
  
• Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting Rotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., & Maloney, D. G. (2009). Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. BLOOD, 113(14), 3383-3391.
  
• Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow Tsao, G. J., Allen, J. A., Logronio, K. A., Lazzeroni, L. C., & Shizuru, J. A. (2009). Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(9), 3288-3293.
  
• The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases Weissman, I. L., & Shizuru, J. A. (2008). The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. BLOOD, 112(9), 3543-3553.
  
• Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Bouvier, M. E., & Maloney, D. G. (2008). Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. BRITISH JOURNAL OF HAEMATOLOGY, 143(3), 395-403.
  
• Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning Sorror, M. L., Storer, B. E., Sandmaier, B. M., Maris, M., Shizuru, J., & Maloney, D. G. (2008). Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. JOURNAL OF CLINICAL ONCOLOGY, 26(30), 4912-4920.
  
• Complementing mutations in core binding factor leukemias: from mouse models to clinical applications Mueller, A., Duque, J., Shizuru, J. A., & Luebbert, M. (2008). Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. ONCOGENE, 27(44), 5759-5773.
  
• Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells Streetz, K. L., Doyonnas, R., Grimm, D., Jenkins, D. D., Fuess, S., & Kay, M. A. (2008). Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells. HEPATOLOGY, 47(2), 706-718.
  
• Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., & Strober, S. (2008). Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation. NEW ENGLAND JOURNAL OF MEDICINE, 358(4), 362-368.
  
• Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., & Maloney, D. G. (2008). Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 26(2), 211-217.
  
• Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma Georges, G. E., Maris, M. B., Maloney, D. G., Sandmaier, B. M., Sorror, M. L., & Storb, R. (2007). Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 13(4), 423-432.
  
• Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation Baron, F., Storb, R., Storer, B. E., Maris, M. B., Niederwieser, D., & Sandmaier, B. M. (2006). Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. JOURNAL OF CLINICAL ONCOLOGY, 24(25), 4150-4157.
  
• Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes Chaparro, R. J., Konigshofer, Y., Beilhack, G. F., Shizuru, J. A., McDevitt, H. O., & Chien, Y.-H. (2006). Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 103(33), 12475-12480.
  
• High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., & Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703-711.
  
• Of mice and men Shizuru, J. A. (2006). Of mice and men. BLOOD, 107(7), 2589-2590.
  
• Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: The effect of postgrafting mycophenolate mofetil dosing Maris, M. B., Sandmaier, B. M., Storer, B. E., Maloney, D. G., Shizuru, J. A., & Storb, R. (2006). Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: The effect of postgrafting mycophenolate mofetil dosing. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(4), 454-465.
  
• Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors Hegenbart, U., Niederwieser, D., Sandmaier, B. M., Maris, M. B., Shizuru, J. A., & STORB, R. (2006). Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. JOURNAL OF CLINICAL ONCOLOGY, 24(3), 444-453.
  
• Protective conditioning for acute graft-versus-host disease Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., & Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321-1331.
  
• Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML Kerbauy, F. R., STORB, R., Hegenbart, U., Gooley, T., Shizuru, J., & Sandmaier, B. M. (2005). Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. LEUKEMIA, 19(6), 990-997.
  
• Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants Beilhack, G. F., Landa, R. R., Masek, M. A., & Shizuru, J. A. (2005). Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants. DIABETES, 54(6), 1770-1779.
  
• Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation Mielcarek, M., Burroughs, L., Leisenring, W., Diaconescu, R., Martin, P. J., & STORB, R. (2005). Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. BRITISH JOURNAL OF HAEMATOLOGY, 129(3), 381-391.
  
• HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia Baron, F., Maris, M. B., Storer, B. E., Sandmaier, B. M., Stuart, M. J., & Storb, R. (2005). HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(4), 272-279.
  
• Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., & Lowsky, R. (2005). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 105(6), 2300-2306.
  
• CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., & Lowsky, R. (2005). CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. EXPERIMENTAL HEMATOLOGY, 33(3), 279-285.
  
• Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease Johnston, L. J., Brown, J., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., & Chao, N. J. (2005). Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 47-55.
  
• Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system Shizuru, J. A., Negrin, R. S., & Weissman, I. L. (2005). Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system. ANNUAL REVIEW OF MEDICINE, 56, 509-538.
  
• Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells Scheffold, C., Scheffold, J. C., Cao, T. M., Gworek, J., & Shizuru, J. A. (2005). Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 1-12.
  
• Approaches to transplantation tolerance in humans Strober, S., Lowsky, R. J., Shizuru, J. A., Scandling, J. D., & Millan, M. T. (2004). Approaches to transplantation tolerance in humans. TRANSPLANTATION, 77(6), 932-936.
  
• Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J., & Horning, S. J. (2004). Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. BLOOD, 103(3), 777-783.
  
• Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice Cao, T. M., Lo, B., Ranheim, E. A., GRUMET, F. C., & Shizuru, J. A. (2003). Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(20), 11571-11576.
  
• Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation Arber, C., Bitmansour, A., Sparer, T. E., Higgins, J. P., Mocarski, E. S., & Brown, J. My. (2003). Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. BLOOD, 102(2), 421-428.
  
• Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation Shilling, H. G., McQueen, K. L., Cheng, N. W., Shizuru, J. A., Negrin, R. S., & Parham, P. (2003). Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. BLOOD, 101(9), 3730-3740.
  
• Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Niederwieser, D., Maris, M., Shizuru, J. A., Petersdorf, E., Hegenbart, U., & Storb, R. F. (2003). Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. BLOOD, 101(4), 1620-1629.
  
• Biology of hematopoietic stem cells and progenitors: Implications for clinical application Kondo, M., Wagers, A. J., Manz, M. G., Prohaska, S. S., Scherer, D. C., & Weissman, I. L. (2003). Biology of hematopoietic stem cells and progenitors: Implications for clinical application. ANNUAL REVIEW OF IMMUNOLOGY, 21, 759-806.
  
• Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice Beilhack, G. F., Scheffold, Y. C., Weissman, I. L., TAYLOR, C., Jerabek, L., & Shizuru, J. A. (2003). Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. DIABETES, 52(1), 59-68.
  
• Kinetics of mixed chimerism in peripheral blood hematopoietic subpopulations from 120 patients after nonmyeloablative hematopoietic stem cell transplant. Little, M. T., Baker, J. E., Sandmaier, B. M., Maris, M. B., Maloney, D., & STORB, R. (2002). Kinetics of mixed chimerism in peripheral blood hematopoietic subpopulations from 120 patients after nonmyeloablative hematopoietic stem cell transplant. BLOOD, 100(11), 39A-39A.
  
• Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion Higuchi, M., Zeng, D. F., Shizuru, J., Gworek, J., Dejbakhsh-Jones, S., & Strober, S. (2002). Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. JOURNAL OF IMMUNOLOGY, 169(10), 5564-5570.
  
• Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases Georges, G. E., Maris, M., Sandmaier, B. M., Maloney, D. G., Feinstein, L., & STORB, R. (2002). Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. INTERNATIONAL JOURNAL OF HEMATOLOGY, 76, 184-189.
  
• Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation Millan, T. Lt., Shizuru, J. A., Hoffmann, P., Dejbakhsh-Jones, S., Scandling, J. D., & Strober, S. (2002). Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. TRANSPLANTATION, 73(9), 1386-1391.
  
• A non-myeloablative conditioning regimen followed by progenitor cell (CD34+) infusion after kidney transplantation can achieve mixed chimerism and immunosuppressive drug withdrawal Millan, M. T., Shizuru, J. A., Hoffmann, P., Dejbakhsh-Jones, S., Scandling, J. D., & Strober, S. (2002). A non-myeloablative conditioning regimen followed by progenitor cell (CD34+) infusion after kidney transplantation can achieve mixed chimerism and immunosuppressive drug withdrawal. FASEB JOURNAL, 16(5), A1030-A1030.
  
• Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients Auffermann-Gretzinger, S., Lossos, I. S., Vayntrub, T. A., Leong, W., GRUMET, F. C., & Shizuru, J. A. (2002). Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. BLOOD, 99(4), 1442-1448.
  
• Non-myeloablative transplantation. Maloney, D. G., Sandmaier, B. M., Mackinnon, S., & Shizuru, J. A. (2002). Non-myeloablative transplantation. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 392-421.
  
• Immunity to infections following hematopoietic cell transplantation Brown, J. M., Weissman, I. L., & Shizuru, J. A. (2001). Immunity to infections following hematopoietic cell transplantation. CURRENT OPINION IN IMMUNOLOGY, 13(4), 451-457.
  
• Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century Maris, M., Woolfrey, A., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., & STORB, R. (2001). Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century. FRONTIERS IN BIOSCIENCE-LANDMARK, 6, G13-G16.
  
• Non-myeloablative hematopoietic stem cell transplantation Maris, M., Sandmaier, B. M., Maloney, D. G., McSweeney, P. A., Woolfrey, A., & Storb, R. (2001). Non-myeloablative hematopoietic stem cell transplantation. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 8(3), 231-234.
  
• Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., & Storb, R. F. (2001). Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. BLOOD, 97(11), 3390-3400.
  
• Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production Baker, J., Verneris, M. R., Ito, M., Shizuru, J. A., & Negrin, R. S. (2001). Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. BLOOD, 97(10), 2923-2931.
  
• Toward regenerative medicine Lagasse, E., Shizuru, J. A., Uchida, N., Tsukamoto, A., & Weissman, I. L. (2001). Toward regenerative medicine. IMMUNITY, 14(4), 425-436.
  
• Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma Verneris, M. R., Ito, M., Baker, E., Arshi, A., Negrin, R. S., & Shizuru, J. A. (2001). Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(10), 532-542.
  
• Nonmyeloablative hematopoietic cell transplantation - Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect Fenstein, L., SANDMAIER, B., Maloney, D., McSweeney, P. A., Maris, M., & STORB, R. (2001). Nonmyeloablative hematopoietic cell transplantation - Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. HEMATOPOIETIC STEM CELLS 2000 BASIC AND CLINICAL SCIENCES, 938, 328-339.
  
• Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease Stuart, M. J., Chao, N. S., Horning, S. J., Wong, R. M., Negrin, R. S., & Goldstein, S. (2001). Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(10), 552-560.
  
• High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., & Stockerl-Goldstein, K. (2001). High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(5), 294-301.
  
• Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century Storb, R., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., & Niederwieser, D. (2000). Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century. TRANSPLANTATION PROCEEDINGS, 32(7), 2548-2549.
  
• Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection Shizuru, J. A., Weissman, I. L., Kernoff, R., Masek, M., & Scheffold, Y. C. (2000). Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 97(17), 9555-9560.
  
• Effect of oral glutamine supplementation during bone marrow transplantation Dickson, T. Mc., Wong, R. M., Negrin, R. S., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. E. (2000). Effect of oral glutamine supplementation during bone marrow transplantation. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 24(2), 61-66.
  
• Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy Hu, W. W., Negrin, R. S., Stockerl-Goldstein, K., JOHNSTON, L. J., Shizuru, J. A., & Blume, K. G. (2000). Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(1), 58-69.
  
• Non-myeloablative haematopoietic stem cell transplants STORB, R., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., & Niederwieser, D. (2000). Non-myeloablative haematopoietic stem cell transplants. HIGH-DOSE THERAPY AND TRANSPLANTATION OF HAEMATOPOIETIC STEM CELLS, 170-174.
  
• Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer Negrin, R. S., Atkinson, K., Leemhuis, T., Hanania, E., Juttner, C., & Klein, J. (2000). Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(3), 262-271.
  
• Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation Cao, T. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., & Hu, W. W. (2000). Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(4), 387-394.
  
• Immune reconstitution Weissman, I. L., & Shizuru, J. A. (1999). Immune reconstitution. NEW ENGLAND JOURNAL OF MEDICINE, 341(16), 1227-1229.
  
• Lymphoid development from stem cells and the common lymphocyte progenitors Akashi, K., Kondo, M., Cheshier, S., Shizuru, J., Gandy, K., & Weissman, I. L. (1999). Lymphoid development from stem cells and the common lymphocyte progenitors. COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 64, 1-12.
  
• Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Dickson, T. M., Kusnierz-Glaz, C. R., Blume, K. G., Negrin, R. S., Hu, W. W., & Stockerl-Goldstein, K. E. (1999). Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biology of blood and marrow transplantation , 5(5), 299-305.
  
• Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Ito, M., & Shizuru, J. A. (1999). Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Biology of blood and marrow transplantation , 5(6), 357-368.
  
• From stem cells to lymphocytes: Biology and transplantation Aguila, H. L., Akashi, K., Domen, J., Gandy, K. L., Lagasse, E., & Weissman, I. L. (1997). From stem cells to lymphocytes: Biology and transplantation. IMMUNOLOGICAL REVIEWS, 157, 13-40.
  
• Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment. Shizuru, J. A., Jerabek, L., Edwards, C. T., & Weissman, I. L. (1996). Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment. Biology of blood and marrow transplantation , 2(1), 3-14.
  
• Anti-CD4 antibodies in diabetes. Shizuru, J. A., & Fathman, C. G. (1993). Anti-CD4 antibodies in diabetes. Immunology series, 59, 237-252.
  
• THE USE OF GRANZYME A AS A MARKER OF HEART-TRANSPLANT REJECTION IN CYCLOSPORINE OR ANTI-CD4 MONOCLONAL ANTIBODY-TREATED RATS CHEN, R. H., IVENS, K. W., Alpert, S., Billingham, M. E., Fathman, C. G., & Griffiths, G. M. (1993). THE USE OF GRANZYME A AS A MARKER OF HEART-TRANSPLANT REJECTION IN CYCLOSPORINE OR ANTI-CD4 MONOCLONAL ANTIBODY-TREATED RATS. TRANSPLANTATION, 55(1), 146-153.
  
• GENETIC-CONTROL OF DIABETES-MELLITUS Weatherall, D., Sarvetnick, N., & Shizuru, J. A. (1992). GENETIC-CONTROL OF DIABETES-MELLITUS. DIABETOLOGIA, 35, S1-S7.
  
• ANTI-CD4 MONOCLONAL-ANTIBODIES IN THERAPY - CREATION OF NONCLASSICAL TOLERANCE IN THE ADULT Shizuru, J. A., Alters, S. E., & Fathman, C. G. (1992). ANTI-CD4 MONOCLONAL-ANTIBODIES IN THERAPY - CREATION OF NONCLASSICAL TOLERANCE IN THE ADULT. IMMUNOLOGICAL REVIEWS, 129, 105-130.
  
• ANTI-CD8 ABROGATES EFFECT OF ANTI-CD4-MEDIATED ISLET ALLOGRAFT SURVIVAL IN RAT MODEL SEYDEL, K., Shizuru, J., Grossman, D., Wu, A., Alters, S., & Fathman, C. G. (1991). ANTI-CD8 ABROGATES EFFECT OF ANTI-CD4-MEDIATED ISLET ALLOGRAFT SURVIVAL IN RAT MODEL. DIABETES, 40(11), 1430-1434.
  
• GENETIC DISSECTION OF T-CELL RECEPTOR-V-BETA GENE REQUIREMENTS FOR SPONTANEOUS MURINE DIABETES Shizuru, J. A., TAYLOREDWARDS, C., Livingstone, A., & Fathman, C. G. (1991). GENETIC DISSECTION OF T-CELL RECEPTOR-V-BETA GENE REQUIREMENTS FOR SPONTANEOUS MURINE DIABETES. JOURNAL OF EXPERIMENTAL MEDICINE, 174(3), 633-638.
  
• TRANSGENIC MICE FOR THE STUDY OF DIABETES-MELLITUS Shizuru, J. A., & Sarvetnick, N. (1991). TRANSGENIC MICE FOR THE STUDY OF DIABETES-MELLITUS. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2(3), 97-104.
  
• GENETIC-ANALYSIS OF DIABETES IN THE NONOBESE DIABETIC MOUSE .1. MHC AND T-CELL RECEPTOR BETA-GENE EXPRESSION Livingstone, A., Edwards, C. T., Shizuru, J. A., & Fathman, C. G. (1991). GENETIC-ANALYSIS OF DIABETES IN THE NONOBESE DIABETIC MOUSE .1. MHC AND T-CELL RECEPTOR BETA-GENE EXPRESSION. JOURNAL OF IMMUNOLOGY, 146(2), 529-534.
  
• INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS TO CARDIAC ALLOGRAFTS IN RATS BY PRETRANSPLANT ANTI-CD4 MONOCLONAL-ANTIBODY THERAPY Shizuru, J. A., Seydel, K. B., Flavin, T. F., Wu, A. P., Kong, C. C., & Fathman, C. G. (1990). INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS TO CARDIAC ALLOGRAFTS IN RATS BY PRETRANSPLANT ANTI-CD4 MONOCLONAL-ANTIBODY THERAPY. TRANSPLANTATION, 50(3), 366-373.
  
• SELECTIVE T-CELL DEPLETION WITH OX-38 ANTI-CD4 MONOCLONAL-ANTIBODY PREVENTS CARDIAC ALLOGRAFT-REJECTION IN RATS Flavin, T., Shizuru, J., SEYDEL, K., Wu, A., Fujimoto, N., & Starnes, V. A. (1990). SELECTIVE T-CELL DEPLETION WITH OX-38 ANTI-CD4 MONOCLONAL-ANTIBODY PREVENTS CARDIAC ALLOGRAFT-REJECTION IN RATS. JOURNAL OF HEART TRANSPLANTATION, 9(5), 482-488.
  
• LOSS OF PANCREATIC-ISLET TOLERANCE INDUCED BY BETA-CELL EXPRESSION OF INTERFERON-GAMMA Sarvetnick, N., Shizuru, J., Liggitt, D., Martin, L., McIntyre, B., & Stewart, T. (1990). LOSS OF PANCREATIC-ISLET TOLERANCE INDUCED BY BETA-CELL EXPRESSION OF INTERFERON-GAMMA. NATURE, 346(6287), 844-847.
  
• THE MOLECULAR-BASIS OF ANTIGEN-SPECIFIC RECOGNITION BY LYMPHOCYTES-T Danska, J. S., Livingstone, A. M., Shizuru, J., & Fathman, C. G. (1990). THE MOLECULAR-BASIS OF ANTIGEN-SPECIFIC RECOGNITION BY LYMPHOCYTES-T. DEFENSE MOLECULES, 121, 241-254.
  
• CARDIAC ALLOGRAFT PROLONGATION IN MICE TREATED WITH COMBINED POSTTRANSPLANTATION TOTAL-LYMPHOID IRRADIATION AND ANTI-L3T4 ANTIBODY THERAPY TRAGER, D. K., Banks, B. A., Rosenbaum, G. E., HOLM, B. I., Shizuru, J. A., & Fathman, C. G. (1989). CARDIAC ALLOGRAFT PROLONGATION IN MICE TREATED WITH COMBINED POSTTRANSPLANTATION TOTAL-LYMPHOID IRRADIATION AND ANTI-L3T4 ANTIBODY THERAPY. TRANSPLANTATION, 47(4), 587-591.
  
• INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE Sarvetnick, N., Shizuru, J., Liggitt, D., & Stewart, T. (1989). INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE. IMMUNOLOGICAL RECOGNITION, PTS 1 AND 2, 54, 837-842.
  
• USE OF ANTI-L3T4 AND ANTI-IA TREATMENTS FOR PROLONGATION OF XENOGENEIC ISLET TRANSPLANTS Kaufman, D. S., Kong, C. S., Shizuru, J. A., Gregory, A. K., & Fathman, C. G. (1988). USE OF ANTI-L3T4 AND ANTI-IA TREATMENTS FOR PROLONGATION OF XENOGENEIC ISLET TRANSPLANTS. TRANSPLANTATION, 46(2), 210-215.
  
• IMMUNOTHERAPY OF THE NONOBESE DIABETIC MOUSE - TREATMENT WITH AN ANTIBODY TO T-HELPER LYMPHOCYTES Shizuru, J. A., TAYLOREDWARDS, C., Banks, B. A., Gregory, A. K., & Fathman, C. G. (1988). IMMUNOTHERAPY OF THE NONOBESE DIABETIC MOUSE - TREATMENT WITH AN ANTIBODY TO T-HELPER LYMPHOCYTES. SCIENCE, 240(4852), 659-662.
  
• ISLET ALLOGRAFT SURVIVAL AFTER A SINGLE COURSE OF TREATMENT OF RECIPIENT WITH ANTIBODY TO L3T4 Shizuru, J. A., Gregory, A. K., CHAO, C. Tb., & Fathman, C. G. (1987). ISLET ALLOGRAFT SURVIVAL AFTER A SINGLE COURSE OF TREATMENT OF RECIPIENT WITH ANTIBODY TO L3T4. SCIENCE, 237(4812), 278-280.
  
• INHIBITION OF RAT MIXED LYMPHOCYTE PANCREATIC-ISLET CULTURES WITH ANTI-IA IMMUNOTOXIN Shizuru, J. A., Ramakrishnan, S., Hunt, T., Merrell, R. C., & Fathman, C. G. (1986). INHIBITION OF RAT MIXED LYMPHOCYTE PANCREATIC-ISLET CULTURES WITH ANTI-IA IMMUNOTOXIN. TRANSPLANTATION, 42(6), 660-666.
  
• STRUCTURE, FUNCTION, AND IMMUNE PROPERTIES OF REASSOCIATED ISLET CELLS Shizuru, J., Trager, D., & Merrell, R. C. (1985). STRUCTURE, FUNCTION, AND IMMUNE PROPERTIES OF REASSOCIATED ISLET CELLS. DIABETES, 34(9), 898-903.